79333-48-5

Usage

Uses

Used in Pharmaceutical Industry:
2-(S)-(3,4-dichloro-phenyl)-4-pentenoic acid is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique structure allows it to be a key component in the synthesis of drugs with specific therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(S)-(3,4-dichloro-phenyl)-4-pentenoic acid serves as a synthetic intermediate in the creation of compounds that help control or prevent the growth of certain pathogens, thereby contributing to crop protection and disease management.
Used in Cancer Research:
2-(S)-(3,4-dichloro-phenyl)-4-pentenoic acid is being researched for its potential as an anti-cancer agent. Its ability to inhibit the growth of certain pathogens suggests that it may also have applications in targeting cancer cells, making it a subject of interest for further scientific exploration and development.

Upstream product

• 173457-29-9 2-(3,4-dichloro-phenyl)-pent-4-enoic acid methyl ester 
• 5807-30-7 3,4-dichlorophenyl acetic acid 
• 106-95-6 allyl bromide 
• 171425-39-1 ethyl 2-(3,4-dichlorophenyl)pent-4-enoate 
• 556-56-9 allyl iodid 
• 6725-44-6 methyl 2-(3,4-dichlorophenyl)acetate 

Downstream Products

• 147643-57-0 (2S)-2-(3,4-dichlorophenyl)pent-4-enoic acid 
• 223905-68-8 (R)-2-(3',4'-dichlorophenyl)pent-4-enoic acid 
• 226917-35-7 C₁₂H₁₁Cl₂NO₃ 
• 1413938-88-1 C₁₃H₁₃Cl₂NO 
• 1413938-62-1 C₁₃H₁₅Cl₂N 
• 1413938-63-2 (R)-3-(3,4-dichlorophenyl)-1-methyl-2,3,4,7-tetrahydro-1H-azepine hydrochloride 
• 1413938-65-4 C₁₂H₁₃Cl₂N 
• 1413938-66-5 C₁₂H₁₃Cl₂N 
• 1413972-79-8 C₁₂H₁₃Cl₂N 
• 1413938-79-0 C₁₂H₁₅Cl₂N 
• 1413938-81-4 (R)-3-(3,4-dichlorophenyl)-1-(2-methoxyethyl)azepane 
• 1413939-02-2 C₁₅H₁₇Cl₂NO 
• 362483-73-6 3-(3,4-dichloro-phenyl)-5-hydroxymethyl-dihydro-furan-2-one 
• 301854-26-2 3-(3,4-dichlorophenyl)-5-methyltetrahydrofuran-2-one 

Relevant academic research and scientific papers

Design, synthesis, and optimization of balanced dual NK1/NK 3 receptor antagonists

In connection with a program directed at potent and balanced dual NK 1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pKi values of 8.6 and 8.1, respectively.

Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity

Herein, we describe the discovery of inhibitors of norepinephrine (NET) and dopamine (DAT) transporters with reduced activity relative to serotonin transporters (SERT). Two compounds, 8b and 21a, along with nomifensine were tested in a rodent receptor occupancy study and demonstrated dose-dependent displacement of radiolabeled NET and DAT ligands. These compounds were efficacious in a rat forced swim assay (model of depression) and also had activity in rat spontaneous locomotion assay.

Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: Synthesis and biological evaluation

Within the continuous quest for the discovery of novel compounds able to treat anxiety and depression, the generation of a pharmacophore model for 5-HT2C receptor antagonists and the discovery of a new class of potent and selective 5-HT2C

Synthesis and structure-antifungal activity relationships of 3-aryl-5-alkyl-2,5-dihydrofuran-2-ones and their carbanalogues: Further refinement of tentative pharmacophore group

Two series of 3-(substituted phenyl)-5-alkyl-2,5-dihydrofuran-2-ones related to a natural product, (-)incrustoporine, were synthesized and their in vitro antifungal activity evaluated. The compounds with halogen substituents on the phenyl ring exhibited selective antifungal activity against the filamentous strains of Absidia corymbifera and Aspergillus fumigatus. On the other hand, the influence of the lenghth of the alkyl chain at C(5) was marginal. The antifungal effect of the most active compound against the above strains was higher than that of ketoconazole, and close to that of amphotericin B. In order to verify the hypothesis about a possible relationship between the Michael-accepting ability of the compounds and their antifungal activity, a series of simple carbanalogues, 2-(substituted phenyl)cyclopent-2-enones, was prepared and subjected to antifungal activity assay as well.

ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY

In one embodiment, this invention provides a novel class of compounds as antagonists of the MCH receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration or one or more of diseases associated with the MCH receptor. An illustrative inventive compound is shown below:

COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY

Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: wherein R1 is hydrogen, hydroxy, fluoro, chloro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy or haloC

3-Phenyl-5-acyloxymethyl-2H,5H-furan-2-ones: Synthesis and biological activity of a novel group of potential antifungal drugs

3-(Substituted phenyl)-5-acyloxymethyl-2H,5H-furan-2-ones related to the natural product (-)-incrustoporine were synthesized and their in vitro antifungal activity evaluated. The compounds with halogen substituents on the phenyl ring displayed much higher antifungal effect against Aspergillus fumigatus than selected representatives of azole antifungal drugs. In particular, the activity (1.34 μg/mL) of the most promising derivative, 3-(3,4-dichlorophenyl)-5-pivaloyloxymethyl-2H,5H-furan-2-one, was comparable to that of amphotericin B (0.5 μg/mL). Preliminary evaluation of the toxicity of the compound was carried out as well. Considering the size and properties of these molecules in comparison with those of amphotericin B, further development of this novel group of antifungals may lead to substances with better pharmacological profiles than that of the standard anti-Aspergillus drug.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes

(2S)-2-(3,4-Dichlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro(2 ,3-dihydrobenzthiophene-3,4′-piperidin-1′yl)]butane S-oxide (3) has been identified as a potent CCR5 antagonist lead structure having an IC50 = 35 nM. Herein, we describe the structure-activity relationship studies directed toward the requirement for and optimization of the C-2 phenyl fragment. The phenyl was found to be important for CCR5 antagonism and substitution was limited to small moieties at the 3-position (13 and 16: X = H, 3-F, 3-Cl, 3-Me).

3-Phenyl-5-methyl-2H,5H-furan-2-ones: Tuning antifungal activity by varying substituents on the phenyl ring

A series of racemic 3-phenyl-5-methyl-2H,5H-furan-2-ones related to a natural product, (-)incrustoporine, was synthesized, and their antifungal activity evaluated. The key structural feature, furanone ring, was closed via H2SO4-mediated cyclization of 2-phenylpent-4-enoic acids. The compounds displayed antifungal activity, especially against filamentous fungi. Expressed as the minimum inhibition concentration (MIC) in μmol/L, the activity of the most promising derivative against Absidia corymbifera matched that of ketoconazole (31.25 μmol/L). In terms of μg/mL, the substance was more active (7.6 μg/mL) than this standard antifungal drug (16.6 μg/mL). (C) 2000 Elsevier Science Ltd. All rights reserved.

Piperidine derivatives useful as neurokinin antagonists

Compounds of formula I STR1 wherein Q1, Q2, Q3, and Q4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.